Evaluation of the Key Advantages Between Two Modalities of Boronophenylalanine Administration for Clinical Boron Neutron Capture Therapy Using an Animal Model

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Sep 9

PMID 36078143

Authors

Yu-Chuan Lin

Yi-Jang Lee

Yi-Wei Chen

Shan-Ying Wang

Fong-In Chou

Affiliations

Soon will be listed here.

Abstract

In clinical boron neutron capture therapy (BNCT), boronophenylalanine (BPA) administrations through one-step infusion (OSI) and two-step infusion (TSI) are the most widely used. This study compared the advantages of OSI and TSI using a human oral squamous cell carcinoma-bearing animal model. OSI was administered at a high-dose rate of 20 mg/kg/min for 20 min (total dose: 400 mg/kg) as the first step infusion. TSI was a prolonged infusion at a low-dose rate of 1.67 mg/kg/min for 15, 30, 45, and 60 min (total dose: 25, 50, 75, and 100 mg/kg) following the first step infusion. The sigmoid model was used to evaluate the boron accumulation effect in the tumor. The advantages of TSI were observed to be greater than those of OSI. The observed advantages of TSI were as follows: a stable level of boron concentration in blood; tumor to blood boron ratio (T/B); tumor to muscle boron ratio (T/M); and skin to blood boron ratio (S/B). The boron accumulation effect in tumors increased to 68.98%. Thus, effective boron concentration in these tumor cells was achieved to enhance the lethal damage in BNCT treatment. Boron concentration in the blood was equal to that in the skin. Therefore, the equivalent dose was accurately estimated for the skin.

Citing Articles

Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated -Dodecaborate on a Rat Brain Tumor Model.

Fujikawa Y, Fukuo Y, Nishimura K, Tsujino K, Kashiwagi H, Hiramatsu R Biology (Basel). 2023; 12(9).

PMID: 37759639 PMC: 10525593. DOI: 10.3390/biology12091240.

Boron Delivery to Brain Cells via Cerebrospinal Fluid (CSF) Circulation in BNCT of Brain-Tumor-Model Rats-Ex Vivo Imaging of BPA Using MALDI Mass Spectrometry Imaging.

Kusaka S, Miyake Y, Tokumaru Y, Morizane Y, Tamaki S, Akiyama Y Life (Basel). 2022; 12(11).

PMID: 36362940 PMC: 9695333. DOI: 10.3390/life12111786.

References

Detta A, Cruickshank G . L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009; 69(5):2126-32. DOI: 10.1158/0008-5472.CAN-08-2345. View

Wada Y, Hirose K, Harada T, Sato M, Watanabe T, Anbai A . Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy. J Radiat Res. 2018; 59(2):122-128. PMC: 5950927. DOI: 10.1093/jrr/rrx080. View

Mager D, Wyska E, Jusko W . Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003; 31(5):510-8. DOI: 10.1124/dmd.31.5.510. View

Ryynanen P, Kortesniemi M, Coderre J, Diaz A, Hiismaki P, Savolainen S . Models for estimation of the (10)B concentration after BPA-fructose complex infusion in patients during epithermal neutron irradiation in BNCT. Int J Radiat Oncol Biol Phys. 2000; 48(4):1145-54. DOI: 10.1016/s0360-3016(00)00766-5. View

Levy G . Kinetics of pharmacologic effects. Clin Pharmacol Ther. 1966; 7(3):362-72. DOI: 10.1002/cpt196673362. View

Levy G . RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. J Pharm Sci. 1964; 53:342-3. DOI: 10.1002/jps.2600530325. View

Wagner J . Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol. 1968; 20(2):173-201. DOI: 10.1016/0022-5193(68)90188-4. View

Watanabe T, Hattori Y, Ohta Y, Ishimura M, Nakagawa Y, Sanada Y . Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [F]-L-FBPA positron emission tomography in boron neutron capture therapy. BMC Cancer. 2016; 16(1):859. PMC: 5100278. DOI: 10.1186/s12885-016-2913-x. View

Ono K, Masunaga S, Kinashi Y, Takagaki M, AKABOSHI M, Kobayashi T . Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys. 1996; 34(5):1081-6. DOI: 10.1016/0360-3016(95)02180-9. View

10.

Chadha M, Capala J, Coderre J, Elowitz E, Iwai J, JOEL D . Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys. 1998; 40(4):829-34. DOI: 10.1016/s0360-3016(97)00891-2. View

11.

Sato E, Yamamoto T, Shikano N, Ogura M, Nakai K, Yoshida F . Intracellular boron accumulation in CHO-K1 cells using amino acid transport control. Appl Radiat Isot. 2014; 88:99-103. DOI: 10.1016/j.apradiso.2013.12.015. View

12.

Fujimura A, Yasui S, Igawa K, Ueda A, Watanabe K, Hanafusa T . In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy. Cells. 2020; 9(10). PMC: 7598271. DOI: 10.3390/cells9102149. View

13.

Koch H, Brown R, Larsson H . The glutamate-activated anion conductance in excitatory amino acid transporters is gated independently by the individual subunits. J Neurosci. 2007; 27(11):2943-7. PMC: 2435202. DOI: 10.1523/JNEUROSCI.0118-07.2007. View

14.

Fukuda H, Hiratsuka J, Kobayashi T, Sakurai Y, Yoshino K, Karashima H . Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med. 2003; 26(3):97-103. DOI: 10.1007/BF03178777. View

15.

Upton R, Mould D . Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e88. PMC: 3917320. DOI: 10.1038/psp.2013.71. View

16.

Chen Y, Lee Y, Lin C, Huang T, Ke S, Mu P . Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series. Life (Basel). 2022; 12(4). PMC: 9025803. DOI: 10.3390/life12040566. View

17.

Chen Y, Lee Y, Lin C, Pan P, Chen J, Wang C . Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan. Biology (Basel). 2021; 10(4). PMC: 8071294. DOI: 10.3390/biology10040334. View

18.

Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M . The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008; 22(6):633-48. DOI: 10.1111/j.1472-8206.2008.00633.x. View

19.

Rosenthal A, Israilevich R, Moy R . Management of acute radiation dermatitis: A review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019; 81(2):558-567. DOI: 10.1016/j.jaad.2019.02.047. View

20.

Sauerwein W, Sancey L, Hey-Hawkins E, Kellert M, Panza L, Imperio D . Theranostics in Boron Neutron Capture Therapy. Life (Basel). 2021; 11(4). PMC: 8070338. DOI: 10.3390/life11040330. View